and lower cost of inventory management. • The third synergy is related to the corporate finance and technology, which could be assessed as 3% of the total synergy value. The strategy consists of cash
% ‐39% 4.4% 81% 14% ‐8.5% ‐20% 30% 64% ‐3.1% 19% ‐16% %YoY ‐8.5% 66% NA 17% ‐67% 13% F C h h f Finan (Bt m Cash ST in Trad Inven Othe Curre Spec Netw Intan Defe Othe Tota
TFRS-15) Total asset was Bt283,593mn in 3Q19, decreased by 2.4% from 4Q18 as spectrum licenses had been amortized. However, some of the effect was negated by an increase in cash. Current liability
comprised of cash and short-term investment amounted to THB 4,035 million, with total liabilities of THB 2,959 million and total equities of THB 9,708 million. In this regard, the company’s financial position
02-634-0135 www.interpharma.co.th 4. MP Financial Statement Balance Sheet (Unit : Baht) 2017 Audited Statement 2018 Audited Statement 2019 Audited Statement Assets Current Assets Cash and cash
8.1% from Dec-20 due to an increase in retained earnings. Cash flow In FY21, Cash flow from operation reported Bt86,634mn increasing 1.2% YoY following EBITDA improvement. Total investing cash flow was
calculation of the transaction size are as follows: Basis Calculation Transaction size (Percent) Net tangible asset basis THB (61.32) million 1/ THB 1,331.27 million 2/ -4.61 Net profit basis This basis cannot
aforementioned transaction is considered as the receipt of financial assistance. The size of the transaction is approximately 0.24 percent of the Company’s Net Tangible Assets (NTA) (NTA of the Company as per the
is equivalent to 0.30% of Company’s Net Tangible Asset (NTA) of THB 2,976.34 million (as of 31 December 2017), which is higher than 0.03% but less than 3% of the Company’s NTA. Hence the Company shall